Rezolute, Inc.'s (NASDAQ:RZLT) Shift From Loss To Profit
Rezolute, Inc. (NASDAQ:RZLT) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The US$532m market-cap company posted a loss in its most recent financial year of US$74m and a latest trailing-twelve-month loss of US$81m leading to an even wider gap between loss and breakeven. As path to profitability is the topic on Rezolute's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
Rezolute is bordering on breakeven, according to the 10 American Biotechs analysts. They anticipate the company to incur a final loss in 2028, before generating positive profits of US$66m in 2029. So, the company is predicted to breakeven approximately 3 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 56%, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
Given this is a high-level overview, we won’t go into details of Rezolute's upcoming projects, however, take into account that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
See our latest analysis for Rezolute
One thing we’d like to point out is that Rezolute has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
Next Steps:
There are key fundamentals of Rezolute which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Rezolute, take a look at Rezolute's company page on Simply Wall St. We've also put together a list of essential aspects you should further examine:
- Valuation: What is Rezolute worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Rezolute is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Rezolute’s board and the CEO’s background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.